State Street’s Kairos Pharma KAPA Stock Holding History

State Street’s Portfolio KAPA Stock Details KAPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.25K	Hold	3,443	–	–	﹤0.01%	4167
2026 Q1	$13.5K	Hold	3,443	–	–	﹤0.01%	4239
2025 Q4	$17.1K	Hold	3,443	–	–	﹤0.01%	4251
2025 Q3	$28.2K	Buy	+3,443	New	+$27.5K	﹤0.01%	4220

Other funds holding KAPA

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SFG

SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

State Street's KAPA Position: Q2 2026 in Review

State Street held its Kairos Pharma (KAPA) position steady in Q2 2026 at 3,443 shares worth $9.25K. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

State Street first reported a position in KAPA in Q3 2025 and has held it in 4 quarters since. The position peaked at $28.2K in Q3 2025. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

State Street held 3,443 shares of Kairos Pharma worth $9.25K as of Q2 2026.
State Street left its Kairos Pharma share count unchanged in Q2 2026.
Kairos Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4167 holding.
State Street first reported a position in Kairos Pharma in Q3 2025 and has held it in 4 quarters since.
State Street's Kairos Pharma position peaked at $28.2K in Q3 2025.
14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.